Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement
- 1 April 2020
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 142, 47-50
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Use of Immune Checkpoint Inhibitors in MesotheliomaCurrent Treatment Options in Oncology, 2019
- OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final AnalysisJournal of Thoracic Oncology, 2018
- Identification of ALK Rearrangements in Malignant Peritoneal MesotheliomaJAMA Oncology, 2018
- FISH Analysis of Crizotinib Target Genes ROS1 / ALK / MET in Malignant MesotheliomaJournal of Thoracic Oncology, 2017
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trialThe Lancet Oncology, 2017
- OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) BiopiesJournal of Thoracic Oncology, 2017
- Brain metastases in malignant pleural mesotheliomaClinical & Experimental Metastasis, 2015
- Second line therapy in malignant pleural mesothelioma: A systematic reviewLung Cancer, 2015
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)PLOS ONE, 2015